NASDAQ:INM InMed Pharmaceuticals (INM) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free INM Stock Alerts $0.26 -0.04 (-14.55%) (As of 03:07 PM ET) Add Compare Share Share Today's Range$0.25▼$0.2750-Day Range$0.27▼$0.4452-Week Range$0.25▼$2.08Volume591,690 shsAverage Volume314,060 shsMarket Capitalization$1.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get InMed Pharmaceuticals alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About InMed Pharmaceuticals Stock (NASDAQ:INM)InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Read More INM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INM Stock News HeadlinesApril 17, 2024 | theglobeandmail.comInMed (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMDMarch 23, 2024 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day ExtensionApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 10, 2024 | markets.businessinsider.comInMed Pharmaceuticals Welcomes New CFO Neeta JagpalFebruary 10, 2024 | msn.comInMed Pharmaceuticals Announces New CFO AppointmentFebruary 9, 2024 | finance.yahoo.comInMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial OfficerJanuary 25, 2024 | benzinga.comInMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet NeedJanuary 18, 2024 | finance.yahoo.comInMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ETApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.December 20, 2023 | finanznachrichten.deInMed Pharmaceuticals: InMed Announces Results of 2023 Annual General MeetingDecember 19, 2023 | finance.yahoo.comInMed Announces Results of 2023 Annual General MeetingNovember 14, 2023 | finance.yahoo.comInMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business UpdateNovember 8, 2023 | msn.comInMed Pharmaceuticals files to sell 12.57M shares for holdersNovember 8, 2023 | morningstar.comInMed Pharmaceuticals Inc INMNovember 2, 2023 | finance.yahoo.comInMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023October 27, 2023 | finance.yahoo.comInMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq RulesOctober 25, 2023 | investorplace.comWhy Is InMed Pharmaceuticals (INM) Stock Down 25% Today?October 24, 2023 | msn.comInMed Pharmaceuticals to raise $5.2M via private placementOctober 24, 2023 | finance.yahoo.comInMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq RulesOctober 24, 2023 | benzinga.comDow Surges 250 Points; US Manufacturing PMI Tops ExpectationsOctober 24, 2023 | benzinga.comWhy InMed Pharmaceuticals Stock Is Soaring TuesdayOctober 3, 2023 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) Releases FY 2023 Report, Shares Corporate UpdateSeptember 29, 2023 | finance.yahoo.comInMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business UpdateSeptember 15, 2023 | benzinga.comThis Clinical Stage BioPharma Is Seeing Solid Growth In Rare Cannabinoid Demand From The Health And Wellness SectorSeptember 7, 2023 | finance.yahoo.comInMed to Present at H.C. Wainwright 25th Annual Global Investment ConferenceJuly 22, 2023 | au.finance.yahoo.comINM - InMed Pharmaceuticals Inc.July 21, 2023 | finance.yahoo.comInMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ETSee More Headlines Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INM CUSIPN/A CIK1728328 Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,950,000.00 Net Margins-115.76% Pretax Margin-115.71% Return on Equity-54.31% Return on Assets-46.23% Debt Debt-to-Equity Ratio0.06 Current Ratio7.03 Quick Ratio6.59 Sales & Book Value Annual Sales$4.14 million Price / Sales0.38 Cash FlowN/A Price / Cash FlowN/A Book Value$3.63 per share Price / Book0.07Miscellaneous Outstanding Shares6,060,000Free Float5,973,000Market Cap$1.57 million OptionableNot Optionable Beta0.10 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Eric A. Adams B.S. Chem. (Age 61)M.I.B., President, CEO & Director Comp: $347.82kMr. Michael Woudenberg P.Eng. (Age 55)Chief Operating Officer Comp: $287.54kMs. Alexandra Diane-Janet Mancini M.Sc. (Age 71)Senior Vice President of Clinical & Regulatory Affairs Comp: $279.39kDr. Sazzad Hossain M.Sc. (Age 66)Ph.D., Co-Founder Comp: $135.99kMs. N. Netta Jagpal (Age 51)CFO & Corporate Secretary Ms. Sarah Li CPACGA, VP of Accounting & ControllerColin ClancySenior Director of Investor RelationsMr. Jerry P. GriffinVice President of Sales & MarketingDr. Eric Chih-Hsien Hsu (Age 54)Senior Vice President of Preclinical Research & Development Comp: $253.46kDr. Shane A. Johnson Ph.D.Senior VP & GM of BayMedicaMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFNeuBase TherapeuticsNASDAQ:NBSEPainReformNASDAQ:PRFXHistogenNASDAQ:HSTOGalmed PharmaceuticalsNASDAQ:GLMDView All CompetitorsInsiders & InstitutionsAndrew HullBought 37,500 shares on 2/21/2024Total: $14,625.00 ($0.39/share)Eric A AdamsBought 41,600 shares on 2/20/2024Total: $14,976.00 ($0.36/share)Armistice Capital LLCBought 205,968 shares on 2/13/2024Ownership: 3.916%View All Insider TransactionsView All Institutional Transactions INM Stock Analysis - Frequently Asked Questions How have INM shares performed in 2024? InMed Pharmaceuticals' stock was trading at $0.4160 at the start of the year. Since then, INM shares have decreased by 37.8% and is now trading at $0.2589. View the best growth stocks for 2024 here. Are investors shorting InMed Pharmaceuticals? InMed Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 114,500 shares, an increase of 1,011.7% from the March 31st total of 10,300 shares. Based on an average trading volume of 350,700 shares, the days-to-cover ratio is presently 0.3 days. View InMed Pharmaceuticals' Short Interest. When is InMed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our INM earnings forecast. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc. (NASDAQ:INM) announced its quarterly earnings data on Tuesday, February, 13th. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $1.24 million for the quarter. InMed Pharmaceuticals had a negative net margin of 115.76% and a negative trailing twelve-month return on equity of 54.31%. When did InMed Pharmaceuticals' stock split? InMed Pharmaceuticals's stock reverse split on the morning of Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of InMed Pharmaceuticals? Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
